trending Market Intelligence /marketintelligence/en/news-insights/trending/wlVBFfKsNa12FqkcW23yFw2 content esgSubNav
In This List

MacroGenics, Synthon Biopharmaceuticals partner on solid tumor targeting drug

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


MacroGenics, Synthon Biopharmaceuticals partner on solid tumor targeting drug

MacroGenics Inc. and Synthon Biopharmaceuticals BV entered a license and collaboration agreement for the development of MGC018, an antibody-drug conjugate directed against solid tumors.

The drug is based on MacroGenics' proprietary B7-H3 antibody and Synthon's proprietary duocarmycin-based, linker-drug technology.

Under the agreement, Synthon has licensed rights to its linker-drug technology to MacroGenics to enable future development and commercialization of MGC018.

Synthon will also provide manufacturing support and supply the antibody-drug conjugate to MacroGenics and will be entitled to receive license fees, milestone payments and royalties based on successful development and commercialization of the drug.